Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CARM | Common Stock | Award | $0 | +185K | $0.00 | 185K | Jul 20, 2021 | Common Stock | 185K | $3.86 | Direct | F1 |
Id | Content |
---|---|
F1 | The option was granted on July 20, 2021 and vests monthly in equal amounts over a three-year period following the grant date. Based on market analysis by Radford of public, pre-commercial biopharmaceutical companies with less than 200 employees and market values between $250 million and $1 billion, the compensation committee of Sesen Bio, Inc. (the "Company") recommended to the Company's board of directors, and the board of directors approved, the amount of the initial grant to the reporting person in connection with the reporting person's appointment as a non-employee director. |